Update shared on 15 Nov 2025
Fair value Increased 2.12%Analysts have increased their price target for Healthcare Realty Trust from $18.90 to $19.30. They cite a modest improvement in projected revenue growth along with a slight reduction in the company’s discount rate.
What's in the News
- Healthcare Realty Trust announced a share repurchase program authorizing up to $500 million in buybacks, valid until October 27, 2026 (Key Developments).
- From July 1, 2025 to September 30, 2025, the company repurchased no new shares. However, it has completed the repurchase of 3,679,162 shares for $63.04 million as part of the ongoing buyback (Key Developments).
- The company updated its 2025 earnings guidance and now expects a loss per share between $0.86 and $0.81, widened from the previous expectation of $0.78 to $0.73 (Key Developments).
- The Board of Directors authorized a new buyback plan as of October 28, 2025 (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has risen slightly from $18.90 to $19.30.
- Discount Rate has decreased modestly, falling from 8.27% to 8.15%.
- Revenue Growth assumptions are improved, with the forecasted decline narrowing from -1.38% to -0.58%.
- Net Profit Margin expectation has decreased, moving from 25.39% to 24.52%.
- Future P/E Ratio is expected to rise from 27.64x to 28.84x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.